Interactions between riluzole and conventional antiepileptic drugs - A comparison of results obtained in the subthreshold method and isobolographic analysis

Journal of Neural Transmission

Volumn 111, Issue 12, 2004, Pages 1511-1522

  Borowicz, K K ^a   Swiader M ^a   Drelewska, E ^a   Czuczwar, S J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Electroshock maximal; Isobolographic analysis; Riluzole

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; RILUZOLE; VALPROIC ACID;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; ELECTRIC SHOCK; GRAND MAL EPILEPSY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ELECTROSHOCK; MALE; MEMORY; MICE; MOTOR ACTIVITY; PHENOBARBITAL; PHENYTOIN; RILUZOLE; SEIZURES; VALPROIC ACID;

EID: 11244269555     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0162-7     Document Type: Article

References (47)

1. Berenbaum MC (1989) What is synergy? Pharmacol Rev 41: 93-141
2. Boissier J-R, Tardy J, Diverres J-C (1960) Une nouvelle methode simple pour explorer l'action 'tranquilisante': le test de la cheminee. Med Exp (Basel) 3: 81-84
3. Borowicz KK, Gasior M, Kleinrok Z, Czuczwar SJ (1995) The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics. Eur J Pharmacol 281: 319-325
4. Bourgeois BFD (1986) Antiepileptic drugs combinations and experimental background: the case of phenobarbital and phenytoin. Naunyn Schmiedebergs Arch Pharmacol 333: 406-411
5. Bourgeois BFD (1988) Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction. J Pharmacol Exp Ther 247: 1128-1132
6. Bracket RL, Pouw B, Blyden JF, Nour M, Matsumoto RR (2000) Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex. Neuropharmacology 39: 407-418
7. Bryson HM, Fulton B, Benfield P (1996) Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 52: 549-563
8. Centonze D, Calabresi P, Pisani A, Marinelli S, Marfia GA, Bernardi G (1998) Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. Neuropharmacology 37: 1063-1070
9. Czechowska G, Dziki M, Pietrasiewicz T, Kleinrok Z, Turski WA, Czuczwar SJ (1993) Competitive antagonists of NMDA receptors, CGP 37849 and CGP 39551, enhance the anticonvulsant activity of valproate against electroconvulsions in mice. Eur J Pharmacol 232: 59-64
10. Czuczwar SJ, Turski WA, Kleinrok Z (1996) Interaction of calcium channel blockers and excitatory amino acid antagonists with conventional antiepileptic drugs. CNS Drug Rev 2: 452-467
11. Czuczwar SJ, Świa̧der M, Kuźniar H, Gasior M, Kleinrok Z (1998a) LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs. Eur J Pharmacol 359: 103-109
12. Czuczwar SJ, Kamiński R, Gasior M, Kozicka M, Zawadzki A, Kleinrok Z (1998b) LY 300164, a novel non-NMDA receptor antagonist, potentiates the anticonvulsive activity of antiepileptic drugs. In: Korczyn AD (ed) 4th Congress, European Society for Clinical Neuropharmacology (Eilat, Israel, December 1-4, 1997). Monduzzi Editore, Bologna, pp 35-39
13. De Sarro G, Siniscalchi A, Ferreri G, Gallelli L, De Sarro A (2000) NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA2/mice. Eur J Pharmacol 408: 25-34
14. Duprat F, Lesage F, Patel AJ, Fink M, Romey G, Lazdunski M (2000) The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK. Mol Pharmacol 57: 906-912
15. Herbert T, Drapeau P, Pradier L, Dunn RJ (1994) Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 45: 1055-1060
16. Jimonet P, Audiau F, Barreau M, Blanchard JC, Boireau A, Bour Y (1999) Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2 benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J Med Chem 29: 2828-2843
17. Kanthasamy AG, Yun RJ, Nguyen B, Truong DD (1999) Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder. J Pharmacol Exp Ther 288: 1340-1348
18. Kretschmer BD, Kratzer U, Schmidt WJ (1998) Riluzole, a glutamate release inhibitor, and motor behavior. Naunyn Schmiedebergs Arch Pharmacol 358: 181-190
19. Kwon JY, Bacher A, Zornow MH (1998) Riluzole does not attenuate increases in hippocampal glutamate concentrations in a rabbit model of repeated transient global cerebral ischemia. Anesth Analg 86: 128-133
20. Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96: 99-113
21. Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3: 285-290
22. Löscher W, Schmidt D (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2: 145-181
23. Luszczki JJ, Czuczwar SJ (2003) Isobolographic and subthreshold methods in the detection of interactions between carbamazepine and conventional antiepileptics - a comparative study. Epilepsy Res 56: 27-42
24. Malgouris C, Daniel M, Doble A (1994) Neuroprotective effects of riluzole on N-methyl-D-aspartate or veratridine-induced neurotoxicity in rat hippocampal slices. Neurosci Lett 177: 95-99
25. Mantz J, Laudenbach V, Lecharny JB, Henzel D, Desmonts JM (1994) Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes. Eur J Pharmacol 257: R7-R8
26. Mary V, Wahl F, Stutzman JM (1995) Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission. Neurosci Lett 201: 92-96
27. Mizoule J, Meldrum B, Mazadier M, Croucher M, Ollat C, Uzan A, Legrand JJ, Gueremy C, Le Fur G (1985) 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. I. Anticonvulsant properties. Neuropharmacology 24: 767-773
28. Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drugs News Perspect 11: 523-569
29. Pietrasiewicz T, Czechowska G, Dziki M, Turski WA, Kleinrok Z, Czuczwar SJ (1993) Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics. Eur J Pharmacol 250: 1-7
30. 5]enkephalin: a synergistic interaction. Eur J Pharmacol 179: 463-468
31. Rogiers V, Akrawi M, Vercruysse A, Philips IR, Shephard EA (1995) Effects of the anticonvulsant, valproate, on the expression of components of the cytochrome P450-mediated monooxygenase system and glutathione S-transferases. Eur J Biochem 15: 337-343
32. Samuel D, Blin O, Dusticier N, Nieoullon A (1992) Effects of riluzole (2-amino-6-trifluoromethoxy benzothiazole) on striatal neurochemical markers in the rat, with special reference to the dopamine, choline, GABA and glutamate synaptosomal high affinity uptake systems. Fund Clin Pharmacol 6: 177-184
33. Sanderink G-J, Bournique B, Stevens J, Petry M, Martinet M (1997) Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther 282: 1465-1472
34. Schmutz M, Portet C, Jeker A (1990) The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent orally active anticonvulsants in rodents. Naunyn Schmiedebergs Arch Pharmacol 342: 61-66
35. Sindou P, Couratier P, Esclaire F, Yardin C, Bousseau A, Hugon J (1994) Prevention of HIV coat protein (gp 120) toxicity in cortical cell cultures by riluzole. J Neurol Sci 126: 133-137
36. Spina E, Pisani F, Perucca E (1996) Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 31: 198-214
37. Steppuhn KG, Turski L (1993) Modulation of the seizure threshold for excitatory amino acid in mice by antiepileptic drugs and chemoconvulsants. J Pharmacol Exp Ther 265: 1063-1070
38. Stutzmann JM, Bohme GA, Gandolfo G, Gottesmann C, Lafforgue J, Blanchard JC, Laduron PM, Lazdunski M (1991) Riluzole prevents hyperexcitability produced by the mast cell degranulating peptide and dendrotoxin I in the rat. Eur J Pharmacol 193: 223-229
39. Tallarida RJ (2002) The interaction index: a measure of drug synergism. Pain 98: 163-168
40. Tallarida RJ, Stone DJ, McCary JD, Raffia RB (1999) Response surfaces analysis of synergism between morphine and clonidine. J Pharmacol Exp Ther 289: 8-13
41. Umemiya M, Berger AJ (1995) Inhibition by riluzole of glycinergic postsynaptic currents in rat hypoglossal motoneurones. Br J Pharmacol 116: 3227-3230
42. Urbańska EM, Dziki M, Kleinrok Z, Czuczwar SJ, Turski WA (1991) Influence of MK-801 on the anticonvulsant activity of antiepileptics. Eur J Pharmacol 200: 277-282
43. Venault P, Chapoutier G, De Carvalho LP, Simiand J, Morre M, Dodd RH, Rossier J (1986) Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature 321: 864-866
44. Wen X, Wang JS, Kivisto KT, Neuvonen PJ, Backman JT (2001) In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 52: 547-553
45. Zona C, Siniscalchi A, Mercuri NB, Bernardi G (1998) Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience 85: 931-938
46. Zarnowski T, Kleinrok Z, Turski WA, Czuczwar SJ (1993) 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock in mice. Neuropharmacology 32: 895-900
47. Zarnowski T, Kleinrok Z, Turski WA, Czuczwar SJ (1994) The competitive NMDA antagonist, D-CPP-ene, potentiates the anticonvulsant activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. Neuropharmacology 33: 619-624